Last reviewed · How we verify

NCT04874363

The Effects of Smoking on Mortality in Patients With Acute Respiratory Syndrome Coronavirus 2 Infection

Completed Last updated 5 May 2021
What this trial tests

trial testing no intervention in Covid19 in 150 participants. Completed in 30 May 2020.

Timeline
15 March 2020
Primary endpoint
15 May 2020
30 May 2020

Quick facts

Lead sponsorSisli Hamidiye Etfal Training and Research Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment150
Start date15 March 2020
Primary completion15 May 2020
Estimated completion30 May 2020
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Sisli Hamidiye Etfal Training and Research Hospital

Who can join

18 and older, any sex, with Covid19 or Smoking. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a retrospective single centered study that was done in the ICU on patients with Covid-19 between 16th of March -16th of May in 2020 Retrospective records will be examined by examining the electronic data files of the patients. There were two groups as smoker and non-smoker.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other Sisli Hamidiye Etfal Training and Research Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04874363.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing